The Science Behind Your Care
Cancer doesn't wait. Neither do we.
For too long, cancer treatment has been guided by population averages — what works for most people, applied to every person. We believed there was a better way. So we built it. Through advanced liquid biopsy, comprehensive tissue profiling, and functional testing on live tumor cells, we give oncologists the molecular clarity to make decisions that are precise, personalized, and evidence-backed — at every stage of the cancer journey.
Our commitment to global quality is anchored by CellDx-Tissue, India’s first and only US FDA-cleared comprehensive genomic profiling (CGP) assay. This milestone is a testament to our vision of delivering world-class analytical rigor, flawless clinical execution, and trusted laboratory excellence to to oncologists and patients across the world.
To transform cancer care through precision oncology. Leveraging advanced molecular science, we aim to make non-invasive blood tests accessible for improved cancer management, especially for those facing advanced cancer.
At Datar Cancer Genetics, we are dedicated to supporting you every step of the way with precision and care.
Since our foundation in India, we have been dedicated to advancing non-invasive cancer detection and personalized therapies.
Began pioneering research on Circulating tumor Cells (CTCs) to create non-invasive methods for early cancer detection and treatment guidance
Expanded our reach to Germany and established a laboratory in the UK to bring our innovative solutions closer to patients worldwide.
Reached key milestones, including FDA Breakthrough Device Designation for TriNetra- Breast, a blood test to screen for breast cancer, and UK recognition for Trublood-Prostate, a non-invasive test for prostate cancer diagnosis.
We accelerated our global reach across more than 50 countries while expanding our advanced diagnostic portfolio. This phase marked the launch of Proxceq—advancing integrated multi-omic tumor profilingand Target-MRD, a highly specialized molecular residual disease detection assay driven by a dual tumor-informed and tumor-agnostic framework.
Achieved FDA clearance for CellDx-Tissue — the only FDA-cleared CGP test in India — marking a significant regulatory milestone and reinforcing clinical credibility in advanced cancer diagnostics
Today, our tests are used by oncologists across 50+ countries to guide treatment
decisions for patients with early stage and advanced cancers.
Founder
Senior Director
Senior Director, Global Strategy
Senior Director, Global Strategy & Medical Affairs
Director
Managing Director, Europe
Director, Research and Innovation
Director, Applications
Consultant Pathologist
Laboratory Director (CLIA)
Laboratory Director
Senior Manager
Director, Research and Innovation
Chief Scientific Officer (USA)
General Manager, Scientific Affairs and Communications
Director, Applications
Consultant Pathologist
Laboratory Director (CLIA)
Senior Manager
Laboratory Director
Medical Oncologist
Medical Oncologist
Breast Cancer Surgeon
Medical Oncologist
Medical Oncologist
Medical Oncologist
Neurosurgeon
Medical Oncologist
Medical Oncologist
Breast Cancer Surgeon
Medical Oncologist
Promoter, Datar Cancer Genetics
[B.Sc., LLB]
Senior Director
[BSc, LLB, Healthcare Management (ISB)]
Senior Director
[MD, FRCP (Glasg.), MCEM, FRSPH (CMQ/ASG)]
Senior Director
[MD (Pathology), MMO (CNIO)]
Director
[LLB]
Director, Research and Innovation
[PhD (Biotechnology), MMO (CNIO)]
Chief Scientific Officer (USA)
[Chemical Engineering), PhD]
General Manager, Scientific Affairs and Communications
[PhD (Biotechnology)]
Managing Director, Europe
[PhD (Medicinal Chemistry)]
Director, Applications
[MBBS, MRCOG, D OBS]
Consultant Pathologist
[MD (Pathology)]
Laboratory Director (CLIA)
[PhD (Chemistry)]
Senior Manager
[MSc (Microbiology), PhD (Medical Microbiology)]
Laboratory Director
[PhD (Biochemistry)]
Medical Oncologist
[BSc, PhD, MBBS, MRCP, FRCP]
Medical Oncologist
[MD, MRCP, FRCR]
Breast Cancer Surgeon
[MS, FRCS]
To fulfill our vision, we have developed a range of non-invasive blood and tissue-based tests that provide personalised insights to guide cancer treatment, helping doctors make informed decisions tailored to each patient.